Norinchukin Bank The Grows Position in Revvity, Inc. (NYSE:RVTY)

Norinchukin Bank The raised its position in Revvity, Inc. (NYSE:RVTY) by 7.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,448 shares of the company’s stock after purchasing an additional 396 shares during the quarter. Norinchukin Bank The’s holdings in Revvity were worth $608,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in RVTY. Tidal Investments LLC lifted its position in shares of Revvity by 2,388.8% during the third quarter. Tidal Investments LLC now owns 52,787 shares of the company’s stock worth $6,744,000 after purchasing an additional 50,666 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Revvity by 3.1% during the 3rd quarter. Principal Financial Group Inc. now owns 141,871 shares of the company’s stock valued at $18,124,000 after buying an additional 4,263 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Revvity by 13.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company’s stock valued at $43,961,000 after buying an additional 41,497 shares during the period. GAMMA Investing LLC increased its position in shares of Revvity by 10.8% during the fourth quarter. GAMMA Investing LLC now owns 1,898 shares of the company’s stock worth $212,000 after acquiring an additional 185 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in shares of Revvity by 8.0% in the fourth quarter. Nordea Investment Management AB now owns 9,681 shares of the company’s stock valued at $1,084,000 after purchasing an additional 719 shares during the period. Institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

NYSE RVTY opened at $92.44 on Wednesday. The firm’s fifty day simple moving average is $105.93 and its two-hundred day simple moving average is $113.61. The firm has a market capitalization of $11.11 billion, a P/E ratio of 41.83, a P/E/G ratio of 3.82 and a beta of 1.07. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a 12-month low of $88.53 and a 12-month high of $129.50.

Revvity (NYSE:RVTY) last announced its earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the business posted $1.25 EPS. Analysts forecast that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity’s payout ratio is currently 12.67%.

Insider Buying and Selling

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the transaction, the insider now owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.68% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Barclays decreased their target price on Revvity from $140.00 to $110.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Wells Fargo & Company decreased their price objective on Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Robert W. Baird lowered their price objective on shares of Revvity from $141.00 to $127.00 and set an “outperform” rating for the company in a research note on Monday. Raymond James reissued an “outperform” rating and set a $145.00 target price (up previously from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Finally, KeyCorp upped their price target on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Revvity currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.50.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.